The antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg, both combined with hydrochlorothiazide (HCTZ) 25 mg, were assessed in a pooled analysis from two large trials with identical study designs in patients with stage 1-2 hypertension. The trials were double-blind with a 4:4:1 randomization scheme to compare once-daily telmisartan 80 mg and HCTZ 25 mg versus once-daily valsartan 160 mg and HCTZ 25 mg versus once-daily placebo on reductions in clinic blood pressure (BP). The primary end point was changes from baseline in BP at the end of 8 weeks. In total, 2121 patients were randomized (telmisartan-HCTZ, 942, valsartan-HCTZ, 952, and placebo, 227) and had baseline seated BPs of 154/102 and 155/102 mm Hg in the two studies, respectively. Changes from baseline in BP after administration of telmisartan-HCTZ (À24.5/ À18.0 mm Hg) were significantly greater than for both placebo (À4.1/À6.5 mm Hg) and valsartan-HCTZ (À22.3/ À16.8 mm Hg) (versus placebo, Po0.0001 for systolic and diastolic BP; versus valsartan-HCTZ, P ¼ 0.0004 for systolic BP and P ¼ 0.0019 for diastolic BP). Adverse event rates were higher in the placebo group than in the active treatment groups (placebo, 41%, telmisartan-HCTZ, 30%, and valsartan-HCTZ, 30%, Po0.05). These data confirm that telmisartan-HCTZ at doses of 80/25 mg lowered systolic and diastolic BP to a greater extent than valsartan-HCTZ at doses of 160/25 mg in stage 1-2 hypertension. The magnitude of the BP-lowering effect provides support for the use of angiotensin receptor blockers with higher doses of a thiazide diuretic (25 mg) to improve hypertension control.
Introduction
Consensus guidelines advocate blood pressure (BP) levels o140/90 mm Hg in patients with hypertension lacking target organ involvement and o130/ 80 mm Hg for those patients who have diabetes mellitus, kidney and heart disease. [1] [2] [3] [4] The use of angiotensin receptor blockers alone or in fixed combinations with low-dose (12.5 mg) hydrochlorothiazide (HCTZ) has become a popular strategy in the management of hypertension as angiotensin receptor blockers are effective antihypertensive agents and have tolerability profiles similar to placebo. 5, 6 Additionally, clinical trials show that the angiotensin receptor blockers reduce cardiovascular events, reduce the proportion of hypertensive patients who develop type 2 diabetes mellitus and prolong survival in conditions such as high-risk vascular disorders, 7, 8 heart failure 9 and diabetic nephropathy. 10, 11 Use of a 25-mg dose of HCTZ in combination with renin-angiotensin blocking agents has been recognised as an effective and well-tolerated strategy to improve BP control, particularly in stage 2 hypertensive patients. 12 In the present analysis, we have evaluated the antihypertensive effects of fixed-dose combinations of the angiotensin receptor blockers telmisartan and valsartan with 25-mg of HCTZ to determine the benefits and tolerability of these increasingly used therapies. As two independent and identically designed trials were completed with these antihypertensive combination strategies 13, 14 we were able to pool the efficacy and safety data from the two trials. This process yielded a substantial sample size of over 2000 patients and had the advantage of greatly increasing the statistical power to examine the antihypertensive efficacy of telmisartan and valsartan with HCTZ.
Methods

Study design
The trials were multicentre, double-blind, doubledummy, randomized, parallel group studies that compared the efficacy and safety of telmisartan with HCTZ 80/25 versus valsartan-HCTZ 160/25 as well as telmisartan-HCTZ 80/25 versus placebo. The first study was conducted at 105 clinical centres in [2004] [2005] , while the second study was conducted at 117 clinical centres in 2006-2007 (all sites were in the United States). Centres that conducted the first trial were allowed to participate in the second trial but study patients who participated in the first trial were not allowed to participate in the second trial. The objectives of the studies were to first determine whether telmisartan-HCTZ 80/25-mg administered once daily was superior to placebo once daily and non-inferior and potentially superior to valsartan-HCTZ 160/25 once daily for reduction in BP using a hierarchical statistical model, described below.
After a 3-4-week run-in period that included a 1-week washout period for patients who were currently receiving antihypertensive therapy followed by a 2-3-week single-blind placebo period to establish baseline BP values, eligible patients were randomized to double-blind treatment of telmisartan 80 mg, valsartan 160 mg or placebo in the ratio of 4:4:1, respectively. After 2 weeks, patients returned to the clinic and up-titrated to telmisartan-HCTZ 80/25, valsartan-HCTZ 160/25 or placebo depending on their initial randomized treatment arm. Starting at the up-titration visit and at 2-week intervals thereafter for a total of an additional 6 weeks, study patients were always examined in the clinic between 0700 and 1000 hours for clinical evaluation (typically 23-26 h postdosing). At every visit, adverse events were also assessed by non-leading questions.
Patient population
Men and women with systemic hypertension were included in the studies if their average seated diastolic BP was X95 mm Hg to o120 mm Hg at the end of the single-blind placebo treatment period. Patients with stroke or myocardial infarction within the past 6 months, congestive heart failure, known or suspected secondary hypertension, poorly controlled diabetes mellitus and chronic kidney failure were excluded from the study.
Measurements of efficacy and safety parameters
The BP was measured by mercury column or aneroid manometry in the seated position at all visits. The pulse rate was measured in conjunction with the BP measurements at each visit. The study coordinators recorded times of medication dosing and BP measurements in the case report forms. Safety was assessed by the evaluation of adverse events and vital signs at each visit of the study, and changes from baseline to the end of the study in laboratory parameters. All reported adverse events were categorized by body system and the preferred term using the Medical Dictionary for Regulatory Activities (MedDRA). 15 The incidence of treatment-emergent adverse effects in each treatment group was tabulated by severity and by their relationship to the study drug (ascertained by the site study personnel). Treatment compliance was assessed by a physical count of returned study medications.
Statistical analyses
All demographic, efficacy and safety data from the two trials were merged into a common database for analysis. The primary end points for assessing efficacy were the changes from baseline to the endof-study visit in clinic diastolic blood pressure (DBP) and systolic blood pressure (SBP) measured 23-26 h after the dosing of study medication. In the case of patients withdrawing from the study before the completion of the 8-week treatment period, lastobservation-carried-forward principles were used.
In order to control for the experiment-wise error rate (a ¼ 0.05), in testing of multiple treatment comparisons (that is, telmisartan-HCTZ 80/25 versus placebo and telmisartan-HCTZ 80/25 versus valsartan-HCTZ 160/25) for both of the primary end points, a hierarchical closed testing procedure was used. All secondary analyses were carried out on the primary end points and all tests on secondary endpoints were carried out at a two-sided a ¼ 0.05. All statistical tests were primarily carried out on the full analysis set involving all patients randomized to the study who had at least one set of BP measurements after titration to combination therapy.
The primary objective of the trials was to show that telmisartan-HCTZ was non-inferior to valsartan-HCTZ. In each of the two studies, assuming a s.d. of 9 mm Hg and a non-inferiority margin of 2 mm Hg for diastolic BP (the generally accepted non-inferiority margin for diastolic BP at the time when the studies were planned), a sample size of 400 completed patients per treatment group had 88% power to show at the 5% (two-sided) level of significance that telmisartan-HCTZ is not inferior to valsartan-HCTZ if both combination treatments were equal. It had been pre-specified in the study protocols that if non-inferiority was proven, confirmatory testing should be carried out to show that telmisartan-HCTZ was superior to valsartan-HCTZ. This hierarchical testing is a closed testing procedure and maintains the type-I error at the prespecified level of 5%. Assuming a 7.5% rate of premature discontinuation from the study and a screen failure rate of 30%, approximately 1320 patients were needed to enroll 920 randomized patients per study. For a superiority comparison with placebo for the active therapies, power was 499% to detect a 5 mm Hg difference in the change from baseline in diastolic BP with 100 placebo patients. In order to be able to assess any centre effects, the studies were designed to randomize nine patients per each of the centre.
It is important to note that the pooled analysis of the two individual studies had a high power to detect even smaller treatment differences than the 2 mm Hg for which the individuals were designed. With the sample size of both studies and the s.d. that was slightly smaller than assumed, there was more than 70% power to establish a difference of 1 mm Hg as statistically different.
The comparability of patients in the three treatment groups was determined from the demographic data and baseline BP values. The primary end points as well as all secondary continuous variables were analysed using an analysis of covariance model involving treatment group with baseline value as a covariate. Further adjustments were made for age, gender and ethnicity for studying the comparative effects of the three treatments. Treatment group comparisons were based on the least-square means obtained through the SAS general linear model procedure (SAS version 8.2, Cary, NC, USA). In addition, effects of age, gender, race and ethnicity on the primary end points were evaluated in sub-group analyses. In a post-hoc analysis, the probability of achieving BP control (DBPo90 mm Hg, SBPo140 mm Hg) depending on baseline BP and treatment was calculated using logistic regression, graphically displayed and statistically assessed.
Results
Patient enrollment and disposition
A total of 4147 patients were screened for the studies. Of the 2295 patients who met the inclusion criteria and were randomized, 2281 received treatment and were randomized to the following treatment arms: 1013 patients to telmisartan-HCTZ, 1012 patients to valsartan-HCTZ, and 256 to placebo. A total of 2042 of the 2281 randomized patients completed the study as planned: (913 (90%) in the telmisartan-HCTZ arm, 931 (92%) in the valsartan-HCTZ arm and 198 (77%) in the placebo arm). Adherence to treatment was similar across all three treatment arms (99%) based on pill counts. The most common reasons for discontinuing the study early were adverse events (112 patients (4.9%)) and withdrawal of consent (54 patients (2.4%)). Thus, 2121 patients had BP measurements available after up-titration to combination treatment and were analyzed for efficacy, 942 patients in the telmisartan-HCTZ arm, 952 patients in the valsartan-HCTZ arm and 227 patients in the placebo arm.
Baseline characteristics of the study population
The baseline characteristics of all randomized and treated patients in the three treatment arms are shown in Table 1 . For the entire patient population the mean age was 53.2 years, with a greater percentage of males (56.8%), was predominantly non-black (74.6%) and with baseline BPs of 154.4/ 101.7 mm Hg. The body mass index (BMI) was increased (31.8 kg m À2 ) in the study population, consistent with the hypertensive population in the USA. There were no significant differences in baseline characteristics among the three treatment arms.
Changes in the clinic trough (24 h post-dose) blood pressure The effects of the three treatment groups in all patients on trough clinic BPs are shown in Figure 1 and Table 2 . Compared with placebo, both combination therapies lowered seated BP substantially. For patients treated with telmisartan-HCTZ 80/25, the reductions in trough clinic BPs Figure 2) . A graphic representation of the probabilities of achieving control based on baseline BP is shown in Figure 3 . There was a statistically greater chance of achieving a systolic BPo140 mm Hg (P ¼ 0.035) or a diastolic BPo90 mm Hg (P ¼ 0.022) on telmisartan-HCTZ 80/25 mg compared with valsartan-HCTZ 160/25 mg.
The effect of age, gender and race on changes in blood pressure Age. The effect of age group (o65 or X65 years old) on reductions in BP for the three treatment groups is shown in Table 3 . Overall, there were no significant treatment-by-age group interactions Adjusted for gender and race group with both baseline response and age as covariates.
Angiotensin II receptor blockers with hydrochlorothiazide 25 mg WB White et al for either systolic or diastolic BP (P ¼ 0.26, 0.35), indicating that treatment differences were consistent across age groups. Significant differences were found between the adjusted mean changes for telmisartan-HCTZ versus valsartan-HCTZ in patients o65 years old. The number of patients in the sub-group X65 years old was insufficient to carry out a meaningful analysis.
Gender. The effect of gender on reductions in BP for the three treatment groups is shown in Table 4 . There were no significant treatment-by-gender interactions found for changes in systolic or diastolic BP (P ¼ 0.43, 0.62). Changes from baseline in the systolic and diastolic BPs were larger on telmisartan-HCTZ versus valsartan-HCTZ in males compared with females.
Race group. The effect of ethnicity group (nonblack and black) on reductions in BP for the three treatment groups is shown in Table 5 . A borderline significant treatment-by-race group interaction was found for diastolic BP (P ¼ 0.05), but not for systolic BP (P ¼ 0.09). The differences between the telmisartan-HCTZ combination and valsartan-HCTZ were not affected by this interaction. Mean changes from baseline in both systolic and diastolic BP were greater for telmisartan-HCTZ versus valsartan-HCTZ in the non-black patients, as well as in the black patients.
Adverse events. The proportion of patients with an adverse event was approximately 31% of the study patients. Of the 2196 patients who were randomized to the study and received at least one dose of study drug, 291 (30%) in the telmisartan-HCTZ arm, 292 (30%) in the valsartan-HCTZ arm and 98 (41%) of placebo patients had any adverse event. For both active treatments the lower incidence rate of patients with at least one adverse event compared with placebo was statistically significant for telmisartan-HCTZ (P ¼ 0.0017) as well as for valsartan-HCTZ (P ¼ 0.0012). The most common adverse events during the trial are shown in Table 6 . There were a total of two deaths reported during either study. One death (sudden death) occurred on the first day of placebo run-in; the cause of the second death was not determined and occurred in a patient 1 week after completion of the trial (the patient had been randomised to the telmisartan-HCTZ arm). There were a total of 44 patients who had a serious adverse event: 19 during screening or placebo run-in, 20 during the double-blind treatment period and five after completion of the trial. Of the 20 patients with a serious adverse event during the double-blind active treatment phase, all but five discontinued prematurely from the trial; no events were determined by the local investigators to be drug-related.
There were no clinically important differences in plasma sodium or potassium among the three treatment groups. The percentages of patients who had any increase in serum uric acid were larger in the active treatment arms (telmisartan-HCTZ: 10.8%, valsartan-HCTZ: 10.3%) than in the placebo group (2.4%). Similarly, the proportion of patients who had any increase in blood urea nitrogen were more common in the active treatment arms (telmisartan-HCTZ: 40%, valsartan-HCTZ: 39%) than in the placebo group (17%).
Discussion
Principal findings
The primary findings from this large, pooled analysis from two independent, identically designed clinical trials showed that telmisartan-HCTZ 80/25 lowered both the systolic and diastolic BP to a significantly greater extent than valsartan-HCTZ 160/25 ( Figure 1 and Table 2 ). In addition, both fixed-dose combination agents lowered BP to a substantially larger extent than placebo. The results of our analysis can be explained in part by the pharmacokinetic profile of telmisartan, which is characterized by a longer half-life than valsartan, 9, 12 and by earlier pharmacodynamic studies using ambulatory BP monitoring that showed greater BP reductions on telmisartan compared with valsartan without the diuretic component. [16] [17] [18] This study also confirms and extends what had been shown regarding the combination therapies for the angiotensin II receptor blockers that use a higher dose of HCTZ (25 mg), 13, 14 an option that has been shown to be increasingly useful in management of clinical hypertension.
3,12
Effects of angiotensin receptor blockers in combination with HCTZ A number of fixed-dose combination therapies of angiotensin receptor blocking agents and diuretics are currently available for the treatment of hypertension. All combinations with the angiotensin receptor blockers were developed initially with HCTZ at a dose of 12.5 mg; these combinations typically show additive effects on blood pressure lowering regardless of which angiotensin receptor blocker was evaluated. 6, [19] [20] [21] [22] [23] [24] Incremental BP-lowering effects have been observed with larger doses of hydrochlorothiazide, that is, 25 mg, in combination with the angiotensin receptor blockers, 6, 19 which led to the development of the fixed-dose combination formulations used in our trial. In an earlier study by Benz and coworkers, 19 valsartan-HCTZ at a dose of 160/25 mg lowered the BP by 22/15 mm Hg compared with 18/ 14 mm Hg for valsartan-HCTZ at a dose of 160/ 12.5 mg. Trenkwalder et al. 25 also showed that patients not controlled on valsartan-HCTZ 160/ 12.5 mg had an additional 8.4/8.3 mm Hg reduction in BP when the diuretic dose was increased to 25 mg. These results are quite similar to those of the present trial (Table 2) , in which valsartan-HCTZ 160/25 lowered the BP by 22/17 mm Hg. In fact, the BP reductions in the two trials 13, 14 were strikingly similar to each other. The baseline BP levels in both treatment groups and demographics of the study population for the two studies were also quite similar. Thus, in spite of the potential for 'equalizing' BP reductions by using HCTZ at 25 mg daily, the differences in BP lowering between the two angiotensin receptor blockers were preserved and account for the differences between the combination therapies.
Study limitations
When the trial was being conducted, the maximal dose of valsartan-HCTZ available in the USA and the rest of the world was 160/25 mg (which is still the case for Europe). However, in the USA, a dose of 320/25 mg valsartan/HCTZ is now registered-this dose may be more effective than the 160/25 mg dose in patients with Stage 2 hypertension.
Conclusions
This substantial analysis, which has pooled data from two large trials in over 2000 patients with hypertension, is useful for establishing the efficacy of the angiotensin receptor blockers with a higher dose of thiazide diuretic (25 mg), as well as for establishing differences in the antihypertensive efficacy of angiotensin receptor blockers. 13, 24 Age, gender and race did not play a substantial role in the differential effects between telmisartan-HCTZ 80/25 and valsartan-HCTZ 160/25. The antihypertensive efficacy differences between telmisartan-HCTZ and valsartan-HCTZ, although small, bear clinical significance. In analyses involving one million adults in 60 prospective studies, the relationship between the reduction in BP and cardiovascular morbidity and mortality events shows that a 2-mm Hg reduction in systolic BP would provide about 10% lower stroke mortality and 7% lower mortality from ischemic heart disease or other vascular death without a BP threshold down to the 115/75-mm Hg level. 1 Cook et al. 26 showed that a 1-mm Hg diastolic BP reduction was associated with a 5% reduction in the risk of coronary heart disease and an 8% reduction in the risk of stroke.
In our study, a limit of 2 mm Hg was used to assess 'non-inferiority' among the treatment groups-this is a value that is generally accepted as a non-inferior margin by regulatory agencies in trials in which diastolic BP is the primary end point. Clearly, a margin of 2 mm Hg is a compromise between the wish not to accept treatments, which may be worse than the comparator, and the feasibility of trial conduct. For example, reducing the non-inferiority margin to 1 mm Hg would quadruple the sample size and make such trials impossible to conduct. Nevertheless, there is evidence 1, [26] [27] [28] that a diastolic BP difference of 1.2 mm Hg translates into reduction in cardiovascular events. Further clinical evidence from the ALLHAT 27 and VALUE 28 therapeutic trials includes the findings that greater reductions in BP induced by one pharmacological regimen versus another showed important clinical implications related to reductions in cardiovascular and cerebrovascular morbidity during a period of less than 1 year. What is known about this topic K The addition of thiazide diuretics to angiotensin receptor blockers (ARB) potentiates the antihypertensive effects of the ARB by increasing RAS activity.
What this study adds By pooling data from two large scale studies, we found that K Both angiotensin receptor blockers (telmisartan and valsartan) have substantial BP lowering effects when combined with hydrochlorothiazide, 25 mg daily. K The angiotensin receptor blocker telmisartan 80 mg lowers the BP greater than valsartan 160 mg when combined with a thiazide diuretic. K The probability of reaching a goal of o 140/90 mmHg is also greater with telmisartan-hydrochlorothiazide compared with valsartan-hydrochlorothiazide.
